Dr. Elmar Maier
Chairman (Independent)

is a seasoned deal maker with a long-standing track record in the life science industry and a reputation of getting deals done.
Elmar founded/co-founded GPC Biotech in 1997, EM Biotech in 2009, iOmx Therapeutics in 2016 and ROSCUE Therapeutics in 2020 and served for over 25 years as CEO, CBO and/or COO. He was involved in raising capital through several private financing rounds, taking GPC public in Europe and the United States, and negotiating multiple asset purchase, M&A and partnering transactions as well as a number of licensing deals generating several hundred million dollars cash upfront in addition to very significant milestone payments and royalties.
Since 1999, Elmar served as a Board member for several life science companies, such as GATC Biotech (acquired by Eurofins in 2017), Panoptes Pharma (acquired by EyeGate Pharma in 2020) and Vetter Pharma.
Elmar holds a degree in Chemistry and obtained his Ph.D. from the University of Konstanz, Germany. He was a Scientist at the ICRF Laboratories in London and Department Head at the Max Planck Institute for Molecular Genetics in Berlin.

Dr. Sebastian Kreuz
Boehringer Ingelheim Venture Fund

studied Technical Biology in Stuttgart (Germany) and holds a PhD in molecular biology and immunology. With more than 15 years of experience in drug discovery within the pharmaceutical industry, he has a strong scientific background in various disease areas and is familiar with a broad range of therapeutic modalities.
Sebastian started his industrial career in 2004 by joining Boehringer Ingelheim (BI) as a research scientist in the functional genomics group, where he established novel experimental platforms based on RNAi and viral vectors for exploration of early drug targets. In the following years, Sebastian held various positions within BI’s R&D organization thereby further broadening his expertise in pharmacology and translational research.
From 2015 to 2019, Sebastian joined BI’s newly formed Research Beyond Borders department to implement a platform concept for virus-based gene therapy as a novel treatment modalitiy for BI. During this time he also established a global collaboration network in the gene therapy space with collaborations in Europe, China and the US.
Sebastian joined the BI venture fund (BIVF) in June 2019. In addition to Quantro Therapeutics, he serves as a board member of Abalos Therapeutics GmbH and Rewind Therapeutics NV.

Dr. Dirk Ullmann
Evotec SE

has more than 22 years’ experience in drug discovery research and collaborative business. In his role as Global Head of Drug Discovery Services he oversees the operational business together with core responsibility for the scientific strategy of the company in Hit Identification, Structure-based Drug Discovery, Protein and Cellular Sciences, ADME-Tox and DMPK, Compound Management, Proteomics and Metabolomics.
Before joining Evotec he held a position as Chief Scientific Officer at Proteros, Munich after initial 11 years with Evotec before. Dirk Ullmann obtained his PhD in Chemistry and Biochemistry from the University of Leipzig, Germany on protease-catalyzed peptide synthesis and did his dost-doctoral training on protein engineering at Brandeis University, Waltham MA, (USA).

Dr. Stefan Ameres
Max Perutz Labs

is a Molecular Biologist and since 2012 Group Leader at the IMBA, Vienna. He received a PhD in 2004 at the Max F. Perutz Laboratories at the University of Vienna, Austria, and undertook his postdoctoral research at the University of Massachusetts Medical School, MA, USA. Stefan has published more than thirty highly regard papers in leading journals with over 3000 citations and delivered more than 60 oral presentations at international conferences. Stefan received several prestigious awards and grants, including the Houska Award (B&C Private Foundation, 2018) and three ERC Grants. In 2016 he was selected as EMBO Young Investigator, and he has been an elected member of the Austrian Academy of Sciences (Young Academy) since 2015.